Emre Pabuccu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emre Pabuccu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Recai Pabuccu
Department of Obstetrics and Gynecology, Ufuk University Faculty of Medicine, Ankara, Turkey
5 shared publicationsRecai Pabuçcu
4 shared publications- Recai Pabuçcu
Department of Obstetrics and Gynecology Ufuk University Dr Rıdvan Ege Hospital Ankara Türkiye
3 shared publications - Ahmet Hakan Haliloğlu
Department of Urology Ufuk University School of Medicine Ankara Turkey
2 shared publications Deniz Han Deniz
Centrum Clinic Assisted Reproduction Center, Ankara, Turkey
2 shared publications- Deniz Han Deniz
Centrum Clinic IVF Center, Ankara, Türkiye
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Reproductive Health
- Vol. 8, 1948337
Follitropin alfa versus follitropin alfa/lutropin alfa (rFSH/rLH) in progestin-primed ovarian stimulation: a prospective two-center observational cohort study
Background: The contribution of recombinant LH during progestin-primed ovarian stimulation (PPOS) remains uncertain. We compared recombinant FSH alone (GON) with recombinant FSH plus recombinant LH (PER) in a prospective two-center observational cohort. Methods: The full enrolled cohort included 213 women (121 GON; 92 PER), including 11 with day-3 transfer. MII oocyte count was the primary outcome. The primary negative binomial model adjusted for female age, AMH, baseline AFC, previous failed cycles and center. Propensity scores used the same covariates; matching was 1:1, exact within center, using Mahalanobis distance within a logit propensity-score caliper. The per-protocol (PP) population comprised the 202 women whose embryos were cultured to day 5; in the full-cohort (ITT) analysis, the 11 women with day-3 transfer contributed zero day-5 blastocysts. Results: The primary adjusted MII incidence rate ratio (IRR) for PER versus GON was 1.01 (95% CI 0.91–1.11; p = 0.910); the PP IRR was 1.00 (95% CI 0.91–1.11; p = 0.939). The number of MII oocytes was similar in both groups (median 11 in both), and this finding did not change after adjustment for baseline characteristics or after propensity-score matching. PER was associated with more day-5 blastocysts (median 4 vs. 3) and more top-quality blastocysts (median 2 vs. 1), and these differences persisted after adjustment and matching. Positive β-hCG rates after the first frozen embryo transfer were similar (47.6% vs. 43.2%). OHSS was rare (1 PER and 2 GON cases, all mild), and no cycle was canceled. Conclusions: No statistically significant difference in MII count was detected, and equivalence was not established. The higher day-5 blastocyst counts associated with PER may reflect an effect of LH on embryo developmental competence rather than on oocyte yield; this exploratory finding does not establish a causal or clinical benefit and requires confirmation in randomized trials. https://clinicaltrials.gov/study/NCT07348757 , NCT07348757.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Reproductive Health
- Vol. 8, 1948337
Open AccessFollitropin alfa versus follitropin alfa/lutropin alfa (rFSH/rLH) in progestin-primed ovarian stimulation: a prospective two-center observational cohort study
Background: The contribution of recombinant LH during progestin-primed ovarian stimulation (PPOS) remains uncertain. We compared recombinant FSH alone (GON) with recombinant FSH plus recombinant LH (PER) in a prospective two-center observational cohort. Methods: The full enrolled cohort included 213 women (121 GON; 92 PER), including 11 with day-3 transfer. MII oocyte count was the primary outcome. The primary negative binomial model adjusted for female age, AMH, baseline AFC, previous failed cycles and center. Propensity scores used the same covariates; matching was 1:1, exact within center, using Mahalanobis distance within a logit propensity-score caliper. The per-protocol (PP) population comprised the 202 women whose embryos were cultured to day 5; in the full-cohort (ITT) analysis, the 11 women with day-3 transfer contributed zero day-5 blastocysts. Results: The primary adjusted MII incidence rate ratio (IRR) for PER versus GON was 1.01 (95% CI 0.91–1.11; p = 0.910); the PP IRR was 1.00 (95% CI 0.91–1.11; p = 0.939). The number of MII oocytes was similar in both groups (median 11 in both), and this finding did not change after adjustment for baseline characteristics or after propensity-score matching. PER was associated with more day-5 blastocysts (median 4 vs. 3) and more top-quality blastocysts (median 2 vs. 1), and these differences persisted after adjustment and matching. Positive β-hCG rates after the first frozen embryo transfer were similar (47.6% vs. 43.2%). OHSS was rare (1 PER and 2 GON cases, all mild), and no cycle was canceled. Conclusions: No statistically significant difference in MII count was detected, and equivalence was not established. The higher day-5 blastocyst counts associated with PER may reflect an effect of LH on embryo developmental competence rather than on oocyte yield; this exploratory finding does not establish a causal or clinical benefit and requires confirmation in randomized trials. https://clinicaltrials.gov/study/NCT07348757 , NCT07348757.
- 17 July 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (8) , 1539-1544
Tubal Pathology on Hysterosalpingography in Women with Unoperated Endometriomas: a Comparative Analysis
This matched comparative study investigates whether unoperated ovarian endometriomas (OMAs) influence the prevalence of tubal pathology as detected by hysterosalpingography (HSG) in infertile women. A total of 266 infertile women with unilateral or bilateral OMAs ≥ 2 cm and 539 matched controls without endometriomas were included between January 2021 and October 2024. Diagnosis of OMAs was confirmed by transvaginal ultrasonography and, if necessary, MRI, and all participants underwent standardized HSG assessment. Tubal pathologies were classified into nine distinct categories. The OMA group showed significantly higher rates of tubal abnormalities (31.6% vs. 10.8%, p < 0.001), with unilateral hydrosalpinx and phimosis being notably more common. Logistic regression identified age and OMA presence as independent predictors, and ROC analysis suggested a cutoff of 4.5 cm for increased risk. These findings indicate that unoperated OMAs, especially when ≥ 4.5 cm, are associated with a markedly increased risk of tubal pathology. Early tubal assessment may be beneficial for individualized fertility planning in this population.
- 17 July 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (8) , 1539-1544
Tubal Pathology on Hysterosalpingography in Women with Unoperated Endometriomas: a Comparative Analysis
This matched comparative study investigates whether unoperated ovarian endometriomas (OMAs) influence the prevalence of tubal pathology as detected by hysterosalpingography (HSG) in infertile women. A total of 266 infertile women with unilateral or bilateral OMAs ≥ 2 cm and 539 matched controls without endometriomas were included between January 2021 and October 2024. Diagnosis of OMAs was confirmed by transvaginal ultrasonography and, if necessary, MRI, and all participants underwent standardized HSG assessment. Tubal pathologies were classified into nine distinct categories. The OMA group showed significantly higher rates of tubal abnormalities (31.6% vs. 10.8%, p < 0.001), with unilateral hydrosalpinx and phimosis being notably more common. Logistic regression identified age and OMA presence as independent predictors, and ROC analysis suggested a cutoff of 4.5 cm for increased risk. These findings indicate that unoperated OMAs, especially when ≥ 4.5 cm, are associated with a markedly increased risk of tubal pathology. Early tubal assessment may be beneficial for individualized fertility planning in this population.
- Open Access
- 22 June 2026
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 18 (2) , 122-124
“Pocket sign” on hysterosalpingography: an adjunctive imaging finding suggestive of caesarean isthmocele
“Pocket sign” on hysterosalpingography: an adjunctive imaging finding suggestive of caesarean isthmocele - Facts, Views and Vision in ObGyn
- 22 June 2026
- Published by Galenos Yayinevi in Human Reproduction Open
- Vol. 18 (2) , 122-124
Open Access“Pocket sign” on hysterosalpingography: an adjunctive imaging finding suggestive of caesarean isthmocele
“Pocket sign” on hysterosalpingography: an adjunctive imaging finding suggestive of caesarean isthmocele - Facts, Views and Vision in ObGyn
- 9 June 2026
- Published by Academician Publishing
- p. 117-122
PCOS’lu İnfertil Hastaların Gonadotropinlerle Yönetimi
- 9 June 2026
- Published by Academician Publishing
- p. 117-122
PCOS’lu İnfertil Hastaların Gonadotropinlerle Yönetimi
- Open Access
- 27 February 2026
- Published by Galenos Yayinevi in Türk Üreme Tıbbı ve Cerrahisi Dergisi
Efficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis
Efficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis - Turkish Journal of Reproductive Medicine and Surgery
- 27 February 2026
- Published by Galenos Yayinevi in Türk Üreme Tıbbı ve Cerrahisi Dergisi
Open AccessEfficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis
Efficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis - Turkish Journal of Reproductive Medicine and Surgery
- Open Access
- 27 February 2026
- Published by Galenos Yayinevi in Türk Üreme Tıbbı ve Cerrahisi Dergisi
Efficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis
Efficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis - Turkish Journal of Reproductive Medicine and Surgery
- 27 February 2026
- Published by Galenos Yayinevi in Türk Üreme Tıbbı ve Cerrahisi Dergisi
Open AccessEfficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis
Efficacy and Safety Profile of Natural Vaginal Progesterone vs. Oral Dydrogesterone in Fresh Embryo Transfer Cycles: A Retrospective Analysis - Turkish Journal of Reproductive Medicine and Surgery
- 13 November 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 179-185
Impact of Follicle Size at Trigger on Reproductive Outcomes in Letrozole-Modified Natural Frozen Embryo Transfer Cycles in High Responder Patients
Purpose To evaluate whether follicle size at hCG trigger influences reproductive outcomes in letrozole-modified natural frozen embryo transfer (let-mNC-FET) cycles among high-responder patients. Methods This observational cohort included 170 let-mNC-FET cycles. Patients were stratified by follicle-size percentiles at trigger: 0–25th (15–17 mm; n = 43), 25–75th (18–20 mm; n = 90), and > 75th (21–24 mm; n = 37). Oral dydrogesterone provided luteal support. Serum progesterone (P4) on embryo-transfer (ET) day was measured with an assay that does not detect dydrogesterone (reflecting endogenous luteal production). The primary outcome was the ongoing pregnancy rate (OPR). Group comparisons used ANOVA/Kruskal–Wallis and χ2 tests; predictors of OPR were evaluated with logistic regression. Results Positive hCG and OPR did not differ across percentile groups (51.2%, 52.2%, 55.6%; p = 0.920 and 48.8%, 50.0%, 52.7%; p = 0.833, respectively). Endometrial thickness at trigger differed by group (medians 8.0, 9.0, 7.8 mm; p < 0.001), while ET-day P4 increased with larger follicles (medians 19.74, 21.00, 26.50 ng/mL; p = 0.001; post-hoc 0–25th vs > 75th p = 0.0009). In multivariable analysis, younger age (aOR 0.834; 95% CI 0.762–0.914; p = 0.0001), higher BMI (aOR 1.169; 1.015–1.346; p = 0.0303), fewer stimulation days (aOR 0.798; 0.647–0.983; p = 0.0343), larger leading follicle size (aOR 1.343; 1.059–1.703; p = 0.0151), and higher ET-day P4 (aOR 1.067; 1.027–1.108; p = 0.0007) independently predicted OPR; EMT and AMH were not associated (p ≥ 0.08 and p = 0.25). Conclusions Although OPR did not differ across follicle-size strata, larger follicle size at trigger and higher endogenous luteal P4 were independent predictors of OPR in highresponders. Confirmation in adequately powered prospective studies is warranted.
- 13 November 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (1) , 179-185
Impact of Follicle Size at Trigger on Reproductive Outcomes in Letrozole-Modified Natural Frozen Embryo Transfer Cycles in High Responder Patients
Purpose To evaluate whether follicle size at hCG trigger influences reproductive outcomes in letrozole-modified natural frozen embryo transfer (let-mNC-FET) cycles among high-responder patients. Methods This observational cohort included 170 let-mNC-FET cycles. Patients were stratified by follicle-size percentiles at trigger: 0–25th (15–17 mm; n = 43), 25–75th (18–20 mm; n = 90), and > 75th (21–24 mm; n = 37). Oral dydrogesterone provided luteal support. Serum progesterone (P4) on embryo-transfer (ET) day was measured with an assay that does not detect dydrogesterone (reflecting endogenous luteal production). The primary outcome was the ongoing pregnancy rate (OPR). Group comparisons used ANOVA/Kruskal–Wallis and χ2 tests; predictors of OPR were evaluated with logistic regression. Results Positive hCG and OPR did not differ across percentile groups (51.2%, 52.2%, 55.6%; p = 0.920 and 48.8%, 50.0%, 52.7%; p = 0.833, respectively). Endometrial thickness at trigger differed by group (medians 8.0, 9.0, 7.8 mm; p < 0.001), while ET-day P4 increased with larger follicles (medians 19.74, 21.00, 26.50 ng/mL; p = 0.001; post-hoc 0–25th vs > 75th p = 0.0009). In multivariable analysis, younger age (aOR 0.834; 95% CI 0.762–0.914; p = 0.0001), higher BMI (aOR 1.169; 1.015–1.346; p = 0.0303), fewer stimulation days (aOR 0.798; 0.647–0.983; p = 0.0343), larger leading follicle size (aOR 1.343; 1.059–1.703; p = 0.0151), and higher ET-day P4 (aOR 1.067; 1.027–1.108; p = 0.0007) independently predicted OPR; EMT and AMH were not associated (p ≥ 0.08 and p = 0.25). Conclusions Although OPR did not differ across follicle-size strata, larger follicle size at trigger and higher endogenous luteal P4 were independent predictors of OPR in highresponders. Confirmation in adequately powered prospective studies is warranted.
- Open Access
- 26 May 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3) , hoaf030
Why does the latest pharmacovigilance data not reflect clinical experience with dydrogesterone?
- 26 May 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3) , hoaf030
Open AccessWhy does the latest pharmacovigilance data not reflect clinical experience with dydrogesterone?
- Open Access
- 11 April 2025
- Published by Galenos Yayinevi in Journal of Turkish Society of Obstetric and Gynecology
- Vol. 22 (2) , 141-146
Unexpected hypo-responders in in vitro fertilization: The impact of higher gonadotropin doses on oocyte yield
Unexpected hypo-responders in in vitro fertilization: The impact of higher gonadotropin doses on oocyte yield - Turkish Journal of Obstetrics and Gynecology
- 11 April 2025
- Published by Galenos Yayinevi in Journal of Turkish Society of Obstetric and Gynecology
- Vol. 22 (2) , 141-146
Open AccessUnexpected hypo-responders in in vitro fertilization: The impact of higher gonadotropin doses on oocyte yield
Unexpected hypo-responders in in vitro fertilization: The impact of higher gonadotropin doses on oocyte yield - Turkish Journal of Obstetrics and Gynecology
- 8 July 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (8) , 2534-2536
Low Dose hCG Support in Modified Natural Frozen Embryo Transfer Cycles
What is the effect of a single low-dose recombinant hCG injection after embryo transfer (ET) in letrozole-induced modified natural frozen embryo transfer cycles (mNC-FET)?. An observational study was conducted in the university-affiliated referral clinic between 2022 and 2024. Women aged 18–42 with at least one vitrified blastocyst obtained from the previous cycle(s) were included. Ovulation induction for endometrial preparation was initiated with oral letrozol (5 mg/day) for five days. Ovulation was triggered using 6500 IU rec hCG sc when the leading follicle > 17 mm, endometrial thickness > 7.5 mm, and serum progesterone (P) < 1.5 ng/ml. All women received 30 mg dydrogesterone/day po for additional five-day luteal support. On the 6th day, ET was performed. Based on a quasi-randomized design, a group of women additionally received a half single bolus of (3250 IU) rec hCG (sc) on the morning of 3rd day of ET (hCG group). Women who did not receive additional hCG were assigned as controls. One hundred fifty-four women were detected to be eligible for the study among 2150 initiated FET cycles during the period. Demographic data of the groups, including mean women’s age, BMI, serum AMH, and infertility etiologies, were comparable in terms of variables. Mean serum progesterone values and the number of transferred embryos were also similar. A significantly higher ongoing pregnancy/started cycle was documented in the hCG group than in controls (46.7% vs 33.6% respectively, p = 0.03*). A single low-dose hCG injection after ET may improve the OPRs of women in letrozole mNC-FET cycles.
- 8 July 2024
- Published by Springer Nature in Reproductive Sciences
- Vol. 31 (8) , 2534-2536
Low Dose hCG Support in Modified Natural Frozen Embryo Transfer Cycles
What is the effect of a single low-dose recombinant hCG injection after embryo transfer (ET) in letrozole-induced modified natural frozen embryo transfer cycles (mNC-FET)?. An observational study was conducted in the university-affiliated referral clinic between 2022 and 2024. Women aged 18–42 with at least one vitrified blastocyst obtained from the previous cycle(s) were included. Ovulation induction for endometrial preparation was initiated with oral letrozol (5 mg/day) for five days. Ovulation was triggered using 6500 IU rec hCG sc when the leading follicle > 17 mm, endometrial thickness > 7.5 mm, and serum progesterone (P) < 1.5 ng/ml. All women received 30 mg dydrogesterone/day po for additional five-day luteal support. On the 6th day, ET was performed. Based on a quasi-randomized design, a group of women additionally received a half single bolus of (3250 IU) rec hCG (sc) on the morning of 3rd day of ET (hCG group). Women who did not receive additional hCG were assigned as controls. One hundred fifty-four women were detected to be eligible for the study among 2150 initiated FET cycles during the period. Demographic data of the groups, including mean women’s age, BMI, serum AMH, and infertility etiologies, were comparable in terms of variables. Mean serum progesterone values and the number of transferred embryos were also similar. A significantly higher ongoing pregnancy/started cycle was documented in the hCG group than in controls (46.7% vs 33.6% respectively, p = 0.03*). A single low-dose hCG injection after ET may improve the OPRs of women in letrozole mNC-FET cycles.